Cablegate: Turkish Patent Institute On Modernization, Ties

This record is a partial extract of the original cable. The full text of the original cable is not available.





E.O. 12958: N/A
SUBJECT: Turkish Patent Institute on Modernization, Ties
with U.S. Counterpart, Zyprexa

Sensitive But Unclassified. Please Handle Accordingly.

1. (SBU) In a November 5 meeting with Econ Couns,
Econoff and Econ Specialist, Turkish Patent Institute
(Turkish acronym TPE) President Yusuf Balci said he
would like to reach out to the U.S. Patent and Trademark
Office (PTO) in the context of his institution's
modernization and development, much of which has been
financed by the World Bank. Econ Couns briefed Balci on
Eli Lilly's Zyprexa issue and urged him to take action
to prevent marketing approval for patent-infringing
generic copies of this drug.

2. (U) Econ Couns paid an introductory call on Yusuf
Balci, President of TPE, which moved into a large and
modern facility in Ankara last spring. Balci told us
that the World Bank had financed a large part of TPE's
modernization project, which included the move to a new

3. (U) TPE is a member of the European Patent Institute
(EPI), and uses EPI and the Russian Patent Institute to
conduct patent searches. Balci stated that he hoped TPE
would gradually begin to take on an increasing share of
these searches in house. Balci hopes that Turkey's EPI
membership and European orientation will not detract
from fruitful cooperation with non-European counterparts
like PTO. Balci participated in the recent PTO-Justice
Ministry workshop on IPR enforcement, and his staff has
said that they plan to nominate an employee for PTO
training to be held in the spring of 2005. Balci told
us that he hopes to go beyond training programs and
seminars, and to engage with PTO in exchange of
expertise and knowhow. Econ Couns undertook to
communicate this desire to PTO.

4. (SBU) Econ Couns took the opportunity to raise Eli
Lilly's concerns about the applications of generic
manufacturers for marketing approval of a copy of
Zyprexa, which has a valid Turkish patent not due to
expire until 2016. The company is concerned that one
application is in the final stages of the approval
process. We provided copies of recent correspondence
initiated by the Ambassador and Senator Lugar on this
problem, and asked Balci to help ensure that the patent
is not infringed. Balci, who was not familiar with the
issue, responded that he had no power to stop marketing
approval by the Health Ministry, but offered to contact
counterparts in that Ministry to convey our concerns.

© Scoop Media

World Headlines


Euro Med Monitor: Syria Cross-border Aid Mechanism Extension Is Necessary For The Survival Of Millions

Permanent members of the UN Security Council should extend the cross-border aid to northwestern Syria, Euro-Med Human Rights Monitor said Tuesday in a statement...

Commonwealth Secretariat: Island Nations Urge Commonwealth Leaders To Bolster Ocean Climate Action
Small island nations are calling for strengthened global support for ocean and climate change action, just days before Commonwealth leaders convene in Kigali, Rwanda... More>>

Climate: ‘Surprise’ Early Heatwave In Europe, Harbinger Of Things To Come

Sweltering conditions in Europe have come earlier than expected this year but the bad news is, they’re the shape of things to come... More>>

World Vision: Deeply Concerned For Thousands Affected By Afghanistan Quake
World Vision is deeply concerned about the deteriorating humanitarian situation in Afghanistan in the wake of a powerful earthquake in the early hours of this morning... More>>

Malaysia: UN Experts Welcome Announcement To Abolish Mandatory Death Penalty

UN human rights experts* today commended an announcement made by the Malaysian government that it will abolish the country’s mandatory death penalty and encouraged Parliament to take concrete steps to pass the agreement into law... More>>

Ukraine: Bachelet Briefs Human Rights Council On Mariupol
Excellencies, Further to Human Rights Council resolution S-34/1 adopted at its 34th Special Session, I present you with an oral update on the grave human rights and humanitarian situation... More>>